Latest Regulatory Approvals News

Propel Funeral Partners has agreed to acquire two historic New Zealand funeral service providers, marking a strategic expansion into new regional markets with an acquisition valued at up to A$7.3 million.

Adriatic Metals has announced a two-tranche institutional placement to raise A$80 million, aiming to fast-track the expansion of its Vares Processing Plant and strengthen its balance sheet ahead of commercial production.

SG Fleet Group Limited reported a 9.8% drop in half-year profit to $41.1 million, while announcing a $3.50 per share acquisition scheme by Pacific Equity Partners' vehicle Westmann Bidco.

Opthea has completed the final patient visit in its pivotal COAST Phase 3 trial evaluating sozinibercept combined with aflibercept for wet AMD, with topline results expected early Q2 2025.

Maximus Resources Limited has issued a Target's Statement recommending shareholders accept Astral Resources NL's off-market takeover bid, which offers a significant premium and improved liquidity. The offer, valuing Maximus shares at approximately $0.073 each, aims to consolidate gold assets in Western Australia under Astral's larger portfolio.

The Star Entertainment Group has received a $650 million debt refinancing proposal from Oaktree Capital Management, offering a potential boost to its liquidity but shadowed by significant conditions and uncertainty.

PYC Therapeutics has launched a A$145.8 million pro-rata accelerated non-renounceable entitlement offer to fund late-stage clinical trials across its pipeline targeting rare diseases with high unmet needs. The capital raise aims to extend the company’s cash runway beyond FY27, supporting four drug candidates through critical human safety and efficacy milestones.

Memphasys has initiated clinical utility testing of its Felix™ System in Brazil through a partnership with Laboratorio Androscience, aiming to establish a foothold in the rapidly growing Latin American IVF sector.

E79 Gold Mines has successfully raised $1.8 million through a placement oversubscribed by more than double, aiming to fund exploration at its promising Laverton South Gold Project and bolster working capital.

Recce Pharmaceuticals reports strong Phase II results for its RECCE® 327 topical gel, achieving a 93% efficacy rate in treating serious skin infections and setting the stage for accelerated Phase 3 trials.

Prodigy Gold NL has unveiled its comprehensive exploration plans for 2025, targeting resource expansion at Hyperion and Tregony deposits while advancing development options at Old Pirate. The company aims to leverage drilling results and metallurgical studies to accelerate project development in the Northern Territory.

FBR Limited’s exclusive joint venture option with CRH Ventures for its Wall as a Service® offering in the US has expired without exercise, freeing the company to pursue independent financing and partnerships across key American markets.